Log in

NASDAQ:MNKDMannKind Stock Price, Forecast & News

-0.06 (-4.00 %)
(As of 06/3/2020 04:00 PM ET)
Today's Range
Now: $1.44
50-Day Range
MA: $1.32
52-Week Range
Now: $1.44
Volume2.19 million shs
Average Volume2.21 million shs
Market Capitalization$306.92 million
P/E RatioN/A
Dividend YieldN/A
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Read More
MannKind logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MNKD



Sales & Book Value

Annual Sales$63.04 million
Book Value($0.92) per share


Net Income$-51,900,000.00


Market Cap$306.92 million
Next Earnings Date8/5/2020 (Estimated)

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

MannKind (NASDAQ:MNKD) Frequently Asked Questions

How has MannKind's stock been impacted by COVID-19 (Coronavirus)?

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 30.9% and is now trading at $1.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MannKind?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MannKind.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MannKind.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) released its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The biopharmaceutical company earned $16.24 million during the quarter, compared to the consensus estimate of $15.15 million. View MannKind's earnings history.

What price target have analysts set for MNKD?

4 brokerages have issued 12-month price targets for MannKind's shares. Their forecasts range from $2.50 to $3.00. On average, they expect MannKind's stock price to reach $2.67 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View analysts' price targets for MannKind.

Has MannKind been receiving favorable news coverage?

News coverage about MNKD stock has trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MannKind earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutMannKind.

Who are some of MannKind's key competitors?

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHK), Gilead Sciences (GILD), Micron Technology (MU), Geron (GERN), NVIDIA (NVDA) and Intel (INTC).

Who are MannKind's key executives?

MannKind's management team includes the following people:
  • Dr. Michael E. Castagna, CEO & Director (Age 42)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 56)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 55)
  • Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 58)
  • Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 52)

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.98%), State Street Corp (1.60%), Geode Capital Management LLC (1.26%), Nuveen Asset Management LLC (0.43%), Dupont Capital Management Corp (0.31%) and Bank of New York Mellon Corp (0.26%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View institutional ownership trends for MannKind.

Which institutional investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Parametric Portfolio Associates LLC, Deutsche Bank AG, BlackRock Inc., Raymond James & Associates, Wells Fargo & Company MN, State Street Corp, and Legal & General Group Plc. View insider buying and selling activity for MannKind.

Which institutional investors are buying MannKind stock?

MNKD stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Geode Capital Management LLC, Advisor Group Holdings Inc., Alliancebernstein L.P., Dupont Capital Management Corp, SG Americas Securities LLC, 180 Wealth Advisors LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross. View insider buying and selling activity for MannKind.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $1.44.

How big of a company is MannKind?

MannKind has a market capitalization of $306.92 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 225 workers across the globe.

What is MannKind's official website?

The official website for MannKind is www.mannkindcorp.com.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.